# Expansion of Invariant NKT Cells for a Cell Immunotherapeutic Approach Allowing the Control of Graft Versus Host-disease and Preserving the Graft Versus Leukemia Effect After Allogeneic Hematopoietic Stem Cell Transplantation

> **NCT03605953** · — · UNKNOWN · sponsor: **Central Hospital, Nancy, France** · enrollment: 134 (estimated)

## Conditions studied

- Allogeneic Hematopoietic Stem Cell (HSC) Transplantation

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03605953
- **Lead sponsor:** Central Hospital, Nancy, France
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-01
- **Primary completion:** 2019-10-01
- **Final completion:** 2021-04-01
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2018-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03605953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03605953, "Expansion of Invariant NKT Cells for a Cell Immunotherapeutic Approach Allowing the Control of Graft Versus Host-disease and Preserving the Graft Versus Leukemia Effect After Allogeneic Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03605953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*